The FDA's alignment on a potential path forward is a positive but non-binding step. Resubmission and eventual approval remain uncertain. Monitor for the Q3 2026 update and any interim data releases for clearer catalysts.
ATRA drugs
ATRA drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 7 $9.93entry
- T+1 · 6mo ago −16.01%α −16.84% · $8.34
- T+5 · 6mo ago +5.54%α +4.03% · $10.48
- T+20 · 6mo ago −3.02%α −6.16% · $9.63
- T+60 · 4mo ago −13.90%α −17.73% · $8.55
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study with an appropriate historical control could support resubmission of the tabelecleucel (tab-cel) BLA. Partner Pierre Fabre plans to submit an updated dataset from the ALLELE study with additional patients and longer follow-up. The company expects a further regulatory update in Q3 2026.
Key Facts
- FDA agreed a single-arm study with historical control could support tab-cel BLA resubmission.
- Pierre Fabre intends to submit updated ALLELE study data with more patients and longer follow-up.
- Next regulatory update expected in Q3 2026.
- Tab-cel BLA received a Complete Response Letter on January 9, 2026.
Financial Impact
No financial figures disclosed; potential upside if resubmission leads to approval, but timeline and probability uncertain.
Risk Factors
- Resubmission may not fully address CRL deficiencies.
- Partner Pierre Fabre controls the BLA and resubmission process.
- No guarantee of eventual FDA approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210413 |
| Document: atra-ex99_1.htm | 0001193125-26-210413 |
| Document: 0001193125-26-210413-index-headers.html | 0001193125-26-210413 |
| Document: 0001193125-26-210413-index.html | 0001193125-26-210413 |
| Document: 0001193125-26-210413.txt | 0001193125-26-210413 |
Track record
11 reports on ATRA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
- Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
- Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
- Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Viewing Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
- Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
- Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
- Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers